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INTRODUCTION  
• There is no uniform criteria to be followed for screening of GDM 
• Among controversy exist between different associations in 
screening for GDM,Screening is essential in all Indian pregnant 
women as there is a increased risk of developing increased glucose 
intolerance during pregnancy. 
• There are both maternal and fetal risk due to uncontrolled 
hyperglycemia during pregnancy. 
• Diabetes in pregnancy increases the risk of obesity and type 2 
diabetes mellitus in the offspring as well as the mother in later part 
of life.Hence glycemic control helps in the prevention of all these 
complications to the mother and the fetus. 
• IADPSG criteria for diagnosis of GDM had been accepted by most 
associations including ADA. WHO criteria is different that of 
IADPSG criteria. Hence the study was conducted to compare the 
two criteria  ADA and WHO for diagnosis of GDM in our 
population. 
• There is controversy regarding screening for GDM in AN mothers. 
• There is no uniform criteria the world . 
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AIMS AND OBJECTIVES: 
Our study is to compare the ADA & WHO Criteria for screening of 
Gestational Diabetes Mellitus. Our objective was to study the 
implications of implementing the ADA guidelines and WHO guidelines 
for screening and diagnosis of GDM in Salem. 
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NEED OF THE STUDY: 
• The better diagnostic criteria for gestational  diabetes mellitus 
remain controversial. 
• It is essential to diagnose GDM early in the pregnancy to avoid 
GDM related complications.  
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REVIEW OF LITERATURE 
1.1 Definition 
1.2 Pathophysiology  
 1.3 Epidemiology 
    1.3.1 International scenario 
    1.3.2 Indian scenario 
1.4 Clinical profile and risk factors 
1.5 Screening 
1.6 Previous studies 
1.7 GDM and obesity 
1.8 Management of GDM 
1.9 Maternal outcomes 
1.10 Fetal outcome 
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1.1 Definition  
Gestational diabetes mellitus (GDM) is defined as “glucose intolerance 
first discovered in pregnancy”[6]. The definition applies whether insulin or 
only diet modification is used for treatment and whether or not the 
condition persists after pregnancy. It does not exclude the possibility that 
unrecognized glucose intolerance may have antedated or begun 
concomitantly with the pregnancy. 
Approximately 7% of all pregnancies are complicated by GDM, resulting 
in more than 200,000 cases annually. The prevalence may range from 1 to 
14% of all pregnancies, depending on the population studied and the 
diagnostic tests employed. 
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1.2 Pathogenesis 
The carbohydrate metabolism undergoes alterations in all normal 
pregnancy to meet the demand of the fetus. The insulin resistance 
increases during second trimester which peaks in third trimester. This is 
due to desensitization of insulin by the placental hormones and weight 
gain (adiposity) occurring in pregnancy[7]. This is counteracted by raise in 
insulin secretion in normal pregnancy. Shortly after pregnancy insulin 
resistance normalises supporting the above said theory. 
      NORMAL GLUCOSE METABOLISM 
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                       ALTERED GLUCOSE METABOLISM 
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In patients with GDM, there are various mechanisms by which play 
a role in causation of GDM. The mechanisms include dysfunction of beta 
cell, chronic insulin resistance and autoimmunity. 
 
Beta cell dysfunction plays a central role that in women with 
GDM the insulin levels does not rise as expected in a normal pregnant 
women. Homko et al[8] and Buchanan et al[9] through their studies have 
proven that chronic beta cell dysfunction underlies the pathogenesis of 
GDM. They had said that steadily as insulin resistance increases in later 
part of pregnancy, there is progressive loss of beta cells as it is unable to 
meet the high insulin demand in GDM women as compared to healthy 
women. Though the etiology is not clear, some studies have tried to relate 
it to genetic causes with alleles linked to calpain-10 gene, sulphonyl urea 
receptor -1 gene() etc.. 
 
Chronic insulin resistance also seems to play a role in 
pathogenesis of GDM. This is due to post receptor signalling defect 
which is thought to be predate pregnancy and this might be helped by 
other factors like obesity[10]. This theory is supported by the fact that after 
delivery the insulin sensitivity normalises in healthy women but not in 
GDM women. 
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Pathophysiology 
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Recently HLA-G also been linked to pathogenesis of GDM which 
is considered to protect the fetus and the antigenic load it renders by 
down regulation of T cells response to fetal trophoblasts[10]. Other rare 
causes include autoimmune destruction of pancreas with autoantibodies 
directed against islet of langerhans (islet cell antibody), beta cell antigens 
(anti - GAD antibodies). Monogenic causes account for less than 10% of 
cases and of that MODY- 2, MODY- 3, MODY- 4 have been linked to 
pathogenesis of GDM.  
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1.3 Epidemiology 
The prevalence varies among different population groups and it depends 
on the criteria used for gestational diabetes. The data is important that 
there has been a 16% - 127% increase in prevalence of GDM over past 20 
years and it helps in planning health schemes and allocating resources. 
1.3.1 International scenario 
In 2010, PRAMS (Pregnancy Risk Assessment Monitoring 
System) in their survey done in United States between 2007-2010 
reported a prevalence of 9.2% for gestational diabetes mellitus. 
Australian institute of health and welfare have reported a prevalence of 
4.6% in 2005-2006[11]. 
1.3.2 Indian scenario 
In India the prevalence varies widely among regions. In a study 
done by Rajput et al in haryana in 2013, the prevalence of GDM was 
7.2%[12]. In a study done in Rajasthan by Kalra et al, the prevalence of 
GDM was 6.6%[13]. In another study done in Tamil Nadu in 2008 by 
Seshiah et al, GDM was detected in 17.8% women in urban, 13.8% 
percent women in semi-urban and 9.9% percent women in rural areas[14]. 
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1.4 Risk factors 
American diabetes association has divided the patients with risk 
factors for GDM into high, average and low risk categories. High risk 
factors are advanced maternal age, obesity, glycosuria, a family history of 
type 2 diabetes and a history of GDM in previous pregnancy. Low risk 
factors include age less than 25 years, normal weight prior to pregnancy, 
ethnic group less prone for GDM, no history of diabetes in first-degree 
relatives and previous GDM, no bad obstetric history[15].Ethnic groups 
like asian, african, american and hispanic women are more prone for 
GDM. 
Other risk factors include short maternal stature, polycystic 
ovarian disease and multiple pregnancies. Some studies have reported 
western type dietary pattern and physical inactivity as risk factors for 
GDM. 
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1.5 Diagnosis of GDM : 
1.5.1 Screening  
Inspite of many studies and evidences we have on GDM, still there 
is arguments between  universal and selective screening for gestational 
diabetes. While ADA advices risk factor based screening dividing the 
patients into high and low risk factor groups, we Indians are at a higher 
risk for gestational diabetes compared to any other population, 
compelling the practice of universal screening in our population. In a 
study by Griffin et al concluded that risk factor based screening missed 
about half the cases and pointed out incidence doubled from 1.45% to 
2.7% by universal screening in the same population [16]. 
Though universal screening may not be feasible in resource poor 
settings, definitely universal screening is expected to improve the 
pregnancy outcomes considering the high prevalence of gestational 
diabetes in india. 
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1.5.2 Diagnostic criteria – evolution  
Many diagnostic criteria have been proposed for gestational 
diabetes in the past 50 years and have been debated always. 
Initially O’Sullivan and Mahan formulated criteria in 1964 which 
recommended 100 g 3 hour oral glucose tolerance test. The threshold 
values were framed based on  ≥2 SD above the mean of normal 
population and its reflection to predict the future risk of diabetes. In late 
1970 s, the National diabetes data group (NDDG)[17] and carpenter & 
cousten[18] modified the values and these values came into practice. The 
National diabetes data group titrated up the blood glucose values by 
15% for the difference in way of analysis of blood glucose. Carpenter and 
cousten criteria had its justifications to alter the threshold values lower 
than the NDDG values and attributed it to change in techniques to 
measure glucose from non glucose substances. In these criteria, GDM 
was diagnosed when 2 out of 4 values were out of range. 
In 2007, there was a major breakthrough when results of HAPO 
study[19] was published. It clarified that adverse pregnancy outcomes 
showed a strong continuous association as a function of maternal 
glycemic levels that were considered below the threshold of gestational 
diabetes. 
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In 2008, IADPSG consensus panel reviewed the results of the 
HAPO study and proposed a diagnostic criterion. The threshold values 
were framed based on the 1.75 times the estimated odds for  birth weight 
>90th percentile, cord C-peptide >90th percentile, and percent body fat 
>90th percentile[20].This criteria was unique that 75 g glucose was used 
and recommendation is that if one value was out of range it is enough to 
label it as gestational diabetes. Other thing was it provided a definition 
for overt diabetes and it was first of the kind to consider pregnancy 
outcomes for framing the threshold values. The new criteria can double 
the prevalence of GDM as it considers one value above range as GDM 
nevertheless considering the impact of adverse outcomes in GDM, ADA 
has recommended IADPSG criteria in its guidelines published in 2011.  
 
  
16 
 
1.5.3  PREVIOUS STUDIES: 
 
There is always a debate about which criteria is better in diagnosing 
GDM. There are few studies to find an answer for this.  
In a study by Haritha[41] et al for comparison of different criteria for 
iagnosis of gestational diabetes mellitus, it was concluded that a single 2 
h plasma glucose is both easy to perform and economical. Also they 
suggested for revised WHO criterion using a 2 h threshold of ≥140 mg % 
to be adopted as a one-step screening and diagnostic procedure for GDM 
in our country. In the St. Carlos Gestational Diabetes Study by Alejandra 
Duran et al, it was found that the application of the new IADPSGC was 
associated with a 3.5-fold increase in GDM prevalence, as well as 
significant improvements in pregnancy outcomes, and was cost-
effective[42]. In another study by Shirazian N et al, they found a higher 
frequency of occurrence of GDM was 6.1% in a 75-g OGTT based on 
ADA criteria, and there was fair agreement between ADA and WHO 
criteria[43]. 
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1.6 GDM and comorbidities 
1.6.1 GDM and obesity:  
Prepregnancy obesity is independently associated with GDM and 
both have their roots to common pathophysiology of hyperglycemia, 
hyperinsulinemia and insulin resistance though obesity also affects 
pregnancy outcomes with other mechanisms other than insulin resistance. 
In HAPO study which included 23,316 women reported an incidence of 
13.7 % for obesity (BMI > 33 kg/m2) and 25% of diagnosed GDM ( 
IADPSG criteria ) mothers were obese[21]. 
In work done by chu et al which was a meta analysis of 20 studies 
concluded that the odds ratio were 2.1, 3.5, 8.5 for overweight, obese and 
severely obese for developing GDM compared to normal pregnancies 
respectively[22].In other words the risk of developing GDM was two, four 
and eight fold higher in overweight, obese and severely obese population 
by the same study. 
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By HAPO study,the maternal complications which were strongly 
associated with both GDM and obesity were preeclampsia, primary 
cesarean delivery and shoulder dystocia. The fetal complications that 
were associated with GDM and obesity were birth weight > 90th 
percentile, cord C peptide > 90th percentile and percent body fat > 90th 
percentile. The mean difference of birth weight between the group with 
GDM and obesity as compared to group with normal weight and normal 
glucose tolerance was 339 grams which was significant[21]. 
The same associations have been proven by randomized controlled 
trials done by Crowther et al[3] and Landon et al[23] that with management 
of GDM, maternal weight gain during pregnancy decreased in the treated 
GDM mothers as compared with the mothers in control group. So 
controlling the weight gain during pregnancy not only reduces the 
perinatal complications in present pregnancy but also in future 
pregnancies through decreased postpartum weight retention. 
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1.7 Management of GDM 
Medical nutrition therapy  
Medical nutrition therapy forms the backbone of management of 
gestational diabetes. ADA recommends individualisation of diet such that 
the calories are met to satisfy the needs of pregnancy and to maintain a 
glycemic goal of fasting blood sugar less than 105 mg/dl, 1 hr less than 
155 mg/dl and 2 hr less than 130 mg/dl[16]. ADA also mentions restriction 
of calories to 30 - 33% and restriction of carbohydrate diet to 35 - 40 % in 
obese women. ACOG recommends a glycemic control which is lower 
than recommended by ADA i.e fasting blood sugar less than 95 mg/dl, 1 
hr less than 140 mg/dl and 2 hr less than 120 mg/dl[23]. 
In a study, 215 women with GDM were randomized to either MNT 
or standard care. Fewer subjects in the MNT group required insulin 
(24.6% vs 31.7%, p = 0.05) 
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Physical activity  
Like in diabetes mellitus there is modest benefit from exercise in 
women with GDM and so it is recommended in GDM light and moderate 
intensity exercise unless contraindicated till later stages of pregnancy. A 
randomised trial carried out in 32 women to circuit type exercise three 
times a week or control, found that resistance training resulted in lower 
postprandial glucose levels and a delay in the requirement of insulin[24]. 
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Insulin 
Insulin is recommended when blood glucose cannot be controlled 
with medical nutrition therapy alone. Basal bolus regimen is considered 
better than twice daily regimen with basal dose generally given in night 
and if needed a dose repeated in morning. The dose of insulin has to be 
individualized as level of insulin resistance varies among individuals with 
requirements higher in later part of third trimester of pregnancy and the 
incidence of hypoglycemia in GDM is lesser compared to type 1 diabetes. 
Human insulin is being used for a long time without any adverse 
effect on the fetus and it does not cross placenta. Newer short acting 
insulin Lispro and Aspart are also now shown to be as effective as human 
insulin and without any adverse effects [25][26]. There is not much data 
available on long acting insulins and their efficacy. 
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Oral hypoglycemics 
Glibenclamide (Glyburide)  
Glibenclamide is considered as effective as insulin and in United 
States it has started replacing insulin. More than half a dozen studies are 
available and these changes are driven by a study done by Langer et al 
which was a randomised trial carried out among 404 women. In that trial 
only 4% in glibenclamide group required additional insulin for control. 
Glibenclamide was not found in cord blood and the percentage of 
neonates with large for gestational age and macrosomia was similar. 
More importantly the incidence of neonatal hypoglycemia and congenital 
anomalies did not differ between groups[27]. 
Metformin  
Metformin is considered at least as effective as insulin and has 
been considered as preferred treatment by women with gestational 
diabetes. Initially the evidences were conflicting until the publication of 
large randomised Metformin in Gestational diabetes (MiG) study done 
among 751 women with GDM[4]. It concluded that neonatal 
complications were similar between metformin and insulin. By that study 
42% required supplemental insulin among metformin group in whom the 
maximum dose was 2500 mg. The numbers of preterm births were 
slightly higher in metformin group though the congenital anomalies did 
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not differ among groups. There are no head to head trials available 
between glyburide and metformin but considering metformin’s insulin 
sensitizing action and decreased gluconeogenesis it theoretically seems to 
be a better choice. 
Postpartum management of GDM 
The blood glucose levels are expected to normalise after delivery 
but GDM women are at higher risk of developing type 2 diabetes later. So 
women who had GDM should undergo regular screening for diabetes 
mellitus. ADA recommends screening after 6-12 weeks after delivery for 
which 75 gm OGTT or fasting blood sugar or HbA1C can be used. A 
lifelong screening every three years has also been recommended [16]. 
Apart from screening, the importance of lifestyle modifications has 
to be stressed to women with GDM. The Finnish Diabetes Prevention 
Study and Diabetes Prevention Program have underlined the importance 
of lifestyle modification that 5-7% weight reduction helps in preventing 
or delaying diabetes in later life[28][29]. 
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1.8 Effects of GDM on Outcomes: 
The effect of overt diabetes is known to be associated with adverse 
maternal and fetal outcome. 
The consequences of GDM over the outcomes had been a 
controversy for a long time until the publication of HAPO study results 
but the association of varying degrees of glycemia related to adverse 
outcome is not clear. In addition to this there might be many confounding 
factors that might be related to adverse outcomes viz., obesity, 
preeclampsia, advanced age and other comorbidities which are usually 
associated with GDM. Nevertheless the adverse outcomes can be divided 
into short and long term effects of GDM on mother and infant. 
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1.8.1 Maternal outcome - short term 
Cesarean section  
GDM women are at increased risk for cesarean section which has 
been evaluated through various studies. But the rates of cesarean section 
are variable across studies done in and out of india. In HAPO study 
primary cesarean section was considered a primary outcome. There was a 
weaker association between primary cesarean section and maternal 
glycemia (odds ratio 1.1)[20]. But other studies showed a significantly 
higher rate of cesarean section in GDM women. In a study done by 
Landon et al[23] on treatment of mild GDM concluded that the cesarean 
rates were in general higher and it was 26% in treatment group against 
33% in routine care group which attained statistical significance. In a 
study done by Mahalakshmi et al which was a retrospective study done 
among 1003 GDM women in tamilnadu reported 41% of elective 
cesarean section and of which 24% were emergency cesarean section[30]. 
  
26 
 
Premature rupture of membranes 
The American College of Obstetricians and Gynecologists have 
classified spontaneous preterm birth into preterm premature rupture of 
membranes, spontaneous preterm labour and cervical incompetence. 
In a study done by Hedderson et al among 46,230 healthy and 
GDM women, spontaneous preterm birth was seen in 4.2% of total 
pregnancies. Among GDM women the spontaneous preterm birth was 
seen in 6.7% of pregnancies. They had found that the rates of 
spontaneous preterm birth were steadily increasing as a function of blood 
glucose levels after adjustment for birth weight, pregnancy induced 
hypertension and polyhydramnios[31]. 
 
Shoulder dystocia  
Shoulder dystocia is defined as “a vaginal cephalic delivery that 
requires additional obstetric manoeuvres to deliver the fetus after the head 
has delivered and gentle traction has failed”[32]. More objective way of 
defining shoulder dystocia is a delay of more than 60 seconds for head to 
body delivery.  
The overall incidence of shoulder dystocia is variable among 
vaginal deliveries and reported between 0.5 - 0.7%[33].It is more common 
in diabetic deliveries and the reported incidence is 2.4%[34].And the risk is 
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two to four fold higher in infants of diabetic mother compared to infants 
of non diabetic mothers of same birth weight[35]. 
Shoulder dystocia has certain risk factors which includes antepartum and 
intrapartum factors viz previous history of shoulder dystocia, 
macrosomia, patient with diabetes or gestational diabetes, BMI>30 kg/m2 
and intrapartum factors like prolonged first or second stage of labour, 
assisted vaginal delivery. Though treating physician should be aware of 
the risk factors, going by the risk factors alone does not prevent shoulder 
dystocia which was the conclusion made by RCOG. 
The management of shoulder dystocia focuses on the mode of 
delivery. It is against the odds of vaginal delivery which might place the 
infant at risk of shoulder dystocia and consequent brachial plexus injury 
against a elective cesarean delivery which has a threefold increased risk 
of postpartum infection and 11 fold increased risk of wound 
complication[34].Considering former the reported incidence of brachial 
plexus injury in macrosomic infants (>4000 g) of diabetic mother allowed 
for vaginal delivery  is 2-5% and of the brachial plexus injury sustained 
only 6.7% persists according to work done by Rouse and owen[36].It is 
recommended that elective cesarean has to be performed for pre-existing 
or gestational diabetes mothers with estimated birth weight of 
4.5kg.Nevertheless it is the fetal risk delivered by vaginal delivery against 
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the maternal morbidity conferred by cesarean delivery. Apart from mode 
of delivery it is known that induction of labour reduces the incidence of 
shoulder dystocia in diabetic patients though not in pregnacies not 
complicated by diabetes with suspected macrosomia. 
The maneuvers used for delivery of shoulder dystocia are beyond the 
scope of this review. 
 
 
 
1.8.2 Long term comorbidities 
 
GDM women have a higher risk of developing type 2 diabetes in 
later life. Around 50 percent of women with GDM go on to develop type 
2 diabetes within five to 10 years. The risk of developing GDM depends 
on many factors which include gestational age at diagnosis, initial 
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maternal glycemia, subsequent pregnancies, obesity and beta cell 
dysfunction. Apart from type 2 diabetes the risk of cardiovascular disease 
and metabolic syndrome is higher in GDM women. 
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Table 1: Risk factor for post partum diabetes 
Ethnicity (e.g. African-American, Latino, Native American, Asian American, Pacific Islander) 
Age at delivery ≥ 33-35 years 
High Parity 
Family history of diabetes 
Duration of follow up after pregnancy 
Testing modality for diagnosing diabetes (e.g. Oral glucose tolerance test, Fasting plasma glucose, Random 
plasma glucose or Hemoglobin A1C) 
Early Diagnosis of gestational diabetes mellitus (< 22-24 weeks) 
Severity of gestational diabetes mellitus: 
- Degree of hyperglycemia in pregnancy and immediately postpartum 
- Total area under the diagnostic Oral glucose tolerance test 
- Number of abnormal Oral glucose tolerance test values 
- Level of fasting blood glucose on the Oral glucose tolerance test 
- Need for pharmacological therapy to achieve glycemic control 
- Elevated fasting glucose level during pregnancy 
Lifestyle parameters: 
- Limited physical activity 
- Consumption of dietary fat 
- Smoking 
Maternal Weight: 
- Pre-pregnancy weight and Body Mass Index 
- Gestational weight gain 
- Postpartum weight retention 
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Table 1: Risk factor for post partum diabetes 
Metabolic syndrome parameters at early postpartum: 
- Waist circumference of 88cm or higher 
- High-density lipoprotein cholesterol > 50mg/dL 
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1.8.3 Fetal outcome  
The infant of diabetic mother is prone for complication during all 
the stages viz fetal, neonatal and adulthood. 
The Pedersen hypothesis states that fetal hyperglycemia is due to 
maternal hyperglycemia as glucose readily crosses placenta. Going by the 
age old hypothesis, the consequences and complications of GDM on fetus 
can be in part explained by maternal glycemic control. The fetal pancreas 
start functioning after 20 weeks of gestation and its known fact maternal 
insulin does not traverse the placental barrier to significant levels. 
Hyperglycemia in mother causes fetal islet hypertrophy and subsequent 
hyperinsulinemia. So the adverse outcomes of infant of diabetic mother 
are due to combined effects of fetal hyperglycemia and hyperinsulinemia. 
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Growth 
In pregnancy complicated by GDM, the fetus is exposed to 
hyperglycemia from mid - second trimester in most patients, followed by 
secondary hyperinsulinemia which takes some weeks for fetal islet cells 
to respond by undergoing islet hypertrophy with an increase in insulin 
production. 
This combination of hyperinsulinemia and hyperglycemia,exerts an 
anabolic effect resulting in a striking increase in fat stores and protein 
stores in third trimester. The resultant effects of these changes culminate 
in weight accretion after 32 weeks of gestation leading to macrosomia. As 
it is known macrosomia poses a greater threat for birth injury because of 
cephalopelvic disproportion. 
 
Fetal oxygenation 
Chronic fetal hyperglycemia and hyperinsulinemia increases the 
fetal basal metabolic rate, with secondary change in erythropoiesis and 
fetal oxygenation. This leads to 30% increase in fetal total body oxygen 
consumption in a relatively oxygen-limited environment[37].Though the 
fetus tries to compensate by increasing its rate of oxidation, the placenta 
has limited ability to increase oxygen delivery to meet the increasing 
demand. This results in relative hypoxemia and fetus again adapts by 
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increasing oxygen carrying capacity which is evident in cord blood by 
elevated cord serum erythropoietin concentration. This results in 
polycythemia. 
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Congenital anomalies 
The structural anomalies commonly occur during first 2 months of 
gestation when organogenesis takes place. So congenital anomalies are 
common in infants born to diabetic mother than in infant of mother with 
GDM. 
 
Neonatal Complications 
Preterm delivery 
Preterm delivery is usually defined as “delivery less than 37 weeks 
gestation”. In the HAPO study, there were 6.9% of preterm deliveries. 
Preterm delivery had weaker association with maternal glucose levels 
with adjusted Odds ratio of 1.05 for fasting glucose levels in the same 
study[19]. 
 
Macrosomia 
Neonatal macrosomia is directly proportional to poor glycemic 
control during pregnancy. Macrosomia in GDM is peculiar compared to 
large for gestational age neonates of normal pregnancy because of the 
deposition of increased fat mass is not proportionate, having higher 
weight than length and head circumference percentiles. These differences 
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in disproportionate growth can be detected through measurements, such 
as the Ponderal Index or the mid-arm-circumference-to-head-
circumference ratio. Macrosomia at birth not only indicates the glycemic 
control of mother but also is a marker for detecting the subsequent 
neonatal morbidity, including polycythemia, hypoglycemia, 
hypocalcemia and intraventricular cardiac septal hypertrophy. 
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CAUDAL REGRESSION SYNDROME 
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CAUDAL REGRESSION SYNDROME 
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In HAPO study, there was a continuous association between 
increasing levels of fasting, 1-hour, and 2-hour plasma glucose of OGTT 
and birth weight above the 90th percentile. Among the primary outcomes 
of HAPO study, odds ratios was highest for birth weight greater than the 
90th percentile (OR 1.38 to 1.46) in relation to increasing levels of 
maternal glycemia[19]. This shows a strong association between birth 
weight and maternal glycemic control. In ACHIOS trial, the average birth 
weight of neonates in treatment group were 3335 g as compared to 3482 
g in routine care group which shows the treatment effect on fetal 
growth[3]. In a study done in india by Kale et al, the average birth weight 
was 2.93 kg compared to 2.80 kg in non-GDM mothers[38]. 
Glucose metabolism 
Hypoglycemia is the frequent metabolic complication and it is common 
in infants with macrosomia and growth retardation. There is a sudden 
interruption of free passage of glucose from mother to fetus post delivery, 
with high neonatal insulin levels. This result in neonatal hypoglycemia in 
case of macrosomic neonates while the cause of hypoglycemia in growth 
retarded neonates is due to depleted glycogen stores and the overall 
incidence seems to be around 50%.The drop in blood glucose usually 
occurs between 1 and 3 hours of life. The definition of hypoglycemia is 
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still controversial. But practitioners recommend to treat infants with 
values less than 40 mg/dL. 
The primary objective should be to prevent neonatal 
hypoglycaemia is by reducing islet cell hyperplasia by maintaining strict 
glycemic control throughout pregnancy. 
 
Calcium and magnesium metabolism 
Hypocalcemia and hypomagnesemia occurs in first 72 hours of 
birth and the incidence is around 50%.Neonates with respiratory distress 
or who had asphyxiated are at higher risk.The cause of hypocalcemia 
might be due to a delay in this postnatal parathyroid hormone response. 
Hypomagnesemia defined as a serum magnesium level < 1.5 mg/dL. It is 
associated usually with hypocalcemia. 
The signs and symptoms of neonatal hypocalcemia and 
hypomagnesemia are similar to those of hypoglycemia and include 
sweating, jitteriness, irritability and seizures except for the little late 
presentation between 24 to 72 hours. Only IDMs with symptomatic 
hypocalcemia and symptomatic hypomagnesemia should be treated. 
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1.8.4 Fetal outcome - long term comorbidities 
The long term issues of infant of diabetic mother are obesity, 
diabetes and neurocognitive impairment in later life. Hillier et al has 
found higher risk of overweight among children of untreated GDM 
women. In children of treated and mild GDM women the risk of 
childhood obesity was not high[39]. Gillman et al in his study among 
infants of mild GDM women have found that though the macrosomia risk 
is high at birth, weight of children does not differ at the end of 5 years[40]. 
The data about the neurocognitive development are limited but it is 
believed infant of diabetic mother have delayed cognitive development 
due to metabolic alterations in utero.  
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METHODOLOGY 
STUDY DESIGN: 
This is a prospective comparative study. 
STUDY POPULATION: 
The study population was selected from ante natal out-patient clinic in the 
department of obstetrics and gynaecology, GMK Medical College & 
Hospital. 
INCLUSION CRITERIA: 
All ante-natal mothers of gestational age 24 to 28 weeks 
EXCLUSION CRITERIA: 
Pre-existing diabetes 
SAMPLE SIZE:  
200 
STUDY PERIOD: 
July 2015 to June 2016 
Laboratory investigations were  performed in the Biochemistry 
Department,GMKMCH, Salem 
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ETHICS:  
The study was conducted in accordance with the ethical rules of 
Government Mohan Kumaramangalam Medical College, Salem. 
Informed written consent to participate in the study was obtained from all 
participants. 
METHODOLOGY: 
All antenatal women attending between 24 and 28 weeks of 
gestation are subjected to fasting blood glucose measurement followed by 
an oral glucose tolerance test (OGTT) using 75 g glucose load. Then 
blood sugar values are collected by venipuncture at the end of 1-h, and 2-
h. The ADA and WHO criteria were applied separately for each subject 
to diagnose GDM. 
According to the ADA criteria, presence of any one of either 
fasting-92 mg/dl (5.1 mmol/L), or 1 h-180 mg/dl (10.0 mmol/L) or 2 h-
153 mg/dl (8.5 mmol/L) was used for diagnosis of GDM. 
According to the WHO criteria, any one of either fasting-126 mg/dl 
(7.0 mmol/L) or 2-h value-140 mg/dl (7.8 mmol/L) was used for 
diagnosis of GDM.  
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This is a point of care study and no further follow ups were done. 
The data obtained will be compared to know the usefulness of the 2 
criterias in diagnosing GDM. 
 
COLLECTION OF SAMPLE: 
Antenatal women  with gestational age between 24 to 28 weeks 
were asked to come in fasting state. Fasting blood sample taken. 75 grams 
glucose given. 1hour and 2 hour blood samples taken. The samples were 
sent to laboratory for immediate processing and reporting.  
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RESULTS:  
 The study was conducted in department of obstetrics and 
gynaecology in government mohan kumaramangalam medical college 
and hospital. A total of 200 patients were included in the study.  Results 
are discussed below 
Clinical characteristics:  
The average age of patients with GDM at presentation was 25 
years. The youngest patient was 19 years and oldest was 40 years. There 
were nine patients aged 20 years or below, 171 patients in the age group 
of 20 to 30 and twenty patients were above the age of 30 years. The 
average gestational age at the time of inclusion in the study was 26.2 
weeks.  The median gravida of patients with GDM was one. Ninety two 
patients were primigravida. 
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Table 1. Patient characteristics: 
Patient characteristics  Mean (SD) Range  
Age (in years) 25.0 (5.5) 19-40 
Height (in cm) 153.1 (7.7) 133-195 
Weight (in kg) 55.5 (10.7) 34-91 
Gestational age (in 
weeks) 
26.2 (1.8) 24-36 
 
 
 
 
Table 2. Age category of the study participants: 
Age of the participants  Total number of participants  
N (%) 
≤20 years  9 (4.6) 
20-30 years  171 (85.3) 
>30 years 20 (10.2) 
Total  200 
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Table 3. Gravida of study participants:  
Gravida  Total number of participants  
N (%) 
1 92 (46.7) 
2 63 (30.5) 
3 33 (16.8) 
4 11 (5.6) 
5 1 (0.5) 
Total  200 
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Diagnosis of GDM by WHO and ADA criteria:  
Among the study population, 28 patients were diagnosed to have 
GDM applying ADA criteria whereas 26 patients by WHO criteria. 
Fig 1. Proportion of GDM patients diagnosed by WHO and ADA criteria:   
 
  
GDM 
identified by 
ADA criteria 
alone 
N= 7 (4.1%) 
 
GDM 
identified by 
WHO criteria 
alone 
N= 5 (19.2) 
 
 
GDM 
identified by 
both WHO 
and ADA 
criteria 
N= 21 (80.8%) 
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Diagnosis by WHO criteria: 
26 patients were diagnosed to have GDM as per WHO criteria. 
Table 4. Proportion study participants diagnosed with gestational diabetes 
mellitus as per WHO criteria: 
 
Gestational diabetes mellitus as per 
WHO criteria 
Total number of participants  
N (%) 
Present  26 (13.2) 
Absent  174 (86.8) 
Total  200 
  
 
 
13.7
86.3
Fig 2. presence of Gestational diabetes 
mellitus as per WHO criteria
Present
Absent
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Diagnosis by ADA criteria: 
28 patients were diagnosed to have GDM as per ADA criteria. 
Table 5. Proportion study participants diagnosed with gestational diabetes 
mellitus as per ADA criteria: 
Gestational diabetes mellitus as per 
ADA criteria 
Total number of participants  
N (%) 
Present  28 (14.2) 
Absent  172 (85.8) 
Total  200 
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Out of 28 cases positive for GDM  by ADA criteria, 
Cases identified by one hour value alone  is 1 case, by two hour value 
alone are 15 cases, both 1 hour and 2 hour are 12 cases. Thus one 
hour value is statistically not significant compared to two hour value. 
ADA 
CRITERIA 
1 HOUR 
VALUE 
ALONE 
BOTH 1HOUR 
AND 2 HOUR 
2 HOUR 
VALUE 
ALONE 
GDM 
PRESENT 
         1                 12                 15 
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GDM diagnosis by the WHO and ADA criteria in the high risk 
group(age above 25 years): 
There was no significant difference in diagnosis of GDM  in 
patients above the age of 25 years. 
 Table 6. Comparison GDM based on WHO and ADA criteria among 
people above 25 years of age (N=78): 
 ADA 
Criteria  
WHO 
Criteria  
GDM 
Present  
WHO 
criteria - 
No GDM  
Chi square  P value  
GDM 
Present  
9 (81.8) 4 (6.0) 0.000 1.000 
No GDM  2 (18.2) 63 (94.0) 
Total  11 (14.1) 67 (85.9)   
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
WHO Criteria 
GDM Present WHO criteria - no 
GDM
81.8
6
18.2
94
fig 3:Comparison GDM based on WHO and ADA criteria among 
people above 25 years of age (N=78)
ADA - No GDM
ADA - GDM Present 
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GDM diagnosis by the WHO and ADA criteria in the high risk 
group(previous history of GDM): 
Of the  patients who had conceived previously, 2 patients had 
history of gestational diabetes 
Table 7. previous history of gestational diabetes mellitus: 
Previous history of gestational 
diabetes mellitus 
Total number of participants  
N (%) 
Present  2 (1) 
Absent  198(99) 
Total  200 
 
  
 
1
99
Fig 4. History of gestational diabetes 
mellitus
Present
Absent
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Table 8. Comparison GDM based on WHO and ADA criteria among 
people with previous history  GDM (N=2): 
 ADA 
Criteria  
WHO 
Criteria  
GDM 
Present  
WHO 
criteria - 
No GDM  
Chi square  P value  
GDM 
Present  
1 (100) 0 (0) 0.000 1.000 
No GDM  0 (0) 1 (100) 
Total  1 (50) 1 (50)   
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
WHO Criteria GDM 
Present
WHO criteria - no GDM
100
0
0
100
fig 5: Comparison GDM based on WHO and ADA criteria among people with previous 
history  GDM (N=2)
ADA - No GDM
ADA - GDM Present 
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GDM diagnosis by the WHO and ADA criteria in the high risk 
group(thyroid disorder): 
Table 9. Thyroid disorders among study participants: 
In the study population , 4 people found to have thyroid dysfunction. Of 
this no patients had GDM. 
Thyroid disorders Total number of participants  
N (%) 
Present  4 (2) 
Absent  196 (98) 
Total  200 
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GDM diagnosis by the WHO and ADA criteria in the high risk group 
(family history of diabetes mellitus): 
 Regarding the family history of diabetes , 30 participants had 
history of diabetes in first degree relatives and 4 had history of diabetes in 
other family members. 
Table 10. Family history of diabetes mellitus: 
Family history of diabetes mellitus Total number of participants  
N (%) 
Diabetes mellitus in father 19 (9.6) 
Diabetes mellitus in mother 16 (8.1) 
Diabetes mellitus in other family 
members  
4 (2.0) 
Total number of pregnant women 
with diabetes mellitus in any family 
members 
34 (17.3) 
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 Out of 34 paticipants who had family history of diabetes,  8 
patients were diagnosed to have GDM in the current pregnancy. And 
among those, ADA and WHO criteria picked up seven patients each. 
Table 11. Comparison GDM based on WHO and ADA criteria among 
people with family history of DM (N=34):  
ADA 
Criteria  
WHO 
Criteria  
GDM 
Present  
WHO 
criteria - 
No GDM  
Chi square  P value  
GDM 
Present  
7 (87.5) 1 (3.8) 23.8 <0.001 
No GDM  1 (12.5) 25 (96.2) 
Total  8 (23.5) 26 (76.5)   
 
9.6
8.1
2
17.3
0
2
4
6
8
10
12
14
16
18
20
Diabetes mellitus in 
father
Diabetes mellitus in 
mother
Diabetes mellitus in 
other family members
Total number of 
pregnant women with 
diabetes mellitus in any 
family members
Fig 6: Family history of diabetes mellitus
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3.8
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96.2
0%
10%
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90%
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WHO - GDM present WHO - No GDM 
fig 7: Comparison GDM based on WHO and ADA criteria among people with 
family history of DM (N=34)
ADA- No GDM
ADA -GDM present 
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GDM diagnosis by the WHO and ADA criteria in the high risk 
group(bad obstetric history): 
Among the study participants , nine percentage of the study population 
had bad obstetric history. 
Table 12. Bad obstetric history among study participants: 
Bad obstetric history Total number of participants  
N (%) 
Present 18 (9) 
Absent 182 (91) 
Total  200 
 
Among the 18 participants who had bad obstetric history, two 
patients was found to have GDM as per WHO criteria and 3 patients as 
per ADA criteria in the current pregnancy. 
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Table 13. Comparison GDM based on WHO and ADA criteria among 
people with previous bad obstetric  history GDM (N=18): 
ADA 
Criteria  
WHO 
Criteria  
GDM 
Present  
WHO 
criteria - 
No GDM  
Chi square  P value  
GDM 
Present  
1 (50) 2 (12.5) 1.80 0.180 
No GDM  1 (50) 14 (87.5) 
Total  2 (11.1) 16 (88.9)   
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fig 8: Comparison GDM based on WHO and ADA criteria among people 
with previous bad obstetric history GDM (N=18)
ADA - No GDM
ADA - GDM Present 
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GDM and the age of the mother: 
There was no significant difference found between the age of the 
mother and occurrence of GDM in this study population 
Table 14. Age distribution between GDM and non GDM mothers 
Test group  Age  GDM 
present  
No GDM  T test  P value  
ADA  Mean 
(SD) 
26.8 (6.1) 24.5 (4.0) 6.62 0.011 
WHO Mean 
(SD) 
27.0 (5.3) 24.7 (5.3) 3.70 0.056 
There was no significant difference found between gestational age and 
the occurrence of GDM. 
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Table 15. Gestational age distribution between GDM and non GDM 
mothers 
Test 
group  
Gestational 
age 
GDM 
present  
No GDM  T test  P value  
ADA  Mean (SD) 26.4 (1.7) 26.1 (3.3) 0.50 0.479 
WHO Mean (SD) 26.4 (1.7) 26.1 (1.8) 0.43 0.513 
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Table 16. Sensitivity and specificity of the ADA criteria compare to Gold 
standard WHO criteria for diabetes mellitus: 
 GDM as per 
WHO criteria  
Non GDM as 
per WHO 
criteria  
Total  
GDM as per 
ADA criteria 
21 (80.8) 7 (4.1) 28  
Non GDM as 
per ADA criteria 
5 (19.2) 167 (95.9) 172 
Total 26 174 200 
 
True positives = 26 
Test positive = 21  
Sensitivity = (Test positive/ True positives)*100 = 21/26=80.8% 
True negatives = 171 
Test negatives = 167 
Specificity = (Test negatives/ True negatives)*100 =164/174=94.25 
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Fig 9: ROC curve for  WHO recommended  and ADA recommended 
blood glucose testing: 
 When plotted for ROC curve for different cut off points in the two 
criterias, blood sugar value at the end of two hours had the highest 
sensitivity and specificity whereas the fasting  blood sugar value had low 
sensitivity and specificity. 
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Data entry and analysis: 
The data was entered in Microsoft excel and analysed using EpiData 
analysis and Stata 12.0 software. The continuous variables like age, 
height, weight and gestational age were expressed with mean and 
standard deviation. The categorical variables like age category, gravida, 
para, history of abortion, bad obstetric history, thyroid disorders 
hypertension, family history of diabetes mellitus and birth weight were 
expressed as proportions. The association between continuous variables 
like age, time duration for delivery since admission and induction of 
labour with method of labour management was tested using independent t 
test. The association between categorical variables such as age, 
gestational age and gestational diabetes mellitus was tested using t test. 
WHO criteria for GDM was used as gold standard to assess the sensitivity 
and specificity of the ADA criteria in diagnosis of GDM. ROC curve was 
obtained for 75gram OGTT, ADA fasting, ADA 1 hour and ADA 2 hour 
blood glucose values. The area under reach curve was compared. The 
association categorical variables such as WHO and ADA identified GDM 
and birth weight was compared using Chi square test.   The p value of 
<0.05 was considered for statistical significance.  
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ADA Vs WHO criteria 
 The purpose of the study was to find out the better diagnostic 
criteria for diagnosing GDM in the general and high risk population. 
General population: 
 28 patients were diagnosed to have GDM by either of the criteria. 
26 were diagnosed by WHO criteria, whereas 28 by ADA criteria. When 
applied to general population, both WHO and ADA criterias performed 
equally in picking up the GDM patients and there was no statistically 
significant difference between the two. 
High risk groups: 
 Sub-group analysis was made by dividing the patients depending 
on their risk factors like age above 25 years, bad obstetric history, 
previous history of GDM, family history of diabetes and associated 
thyroid disorders.  
Age above 25 years: 
 78 patients were above the age of 25 years and considered high risk 
for developing GDM. And among these 78 patients, 13 patients were 
diagnosed to have GDM. Though in this study only 16.5 percent of the 
patients above the age of 254 were found to have GDM, age above 25 
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years is definitely a high risk factor for GDM. There was no statistical 
difference between WHO and ADA criteria in diagnosing GDM in 
patients above the age 25 years.  
Past history of GDM: 
 Patients who had GDM in the previous pregnancies have a very 
high risk of getting GDM in the subsequent pregnancies. This should be 
considered by the women with history of GDM with high regard when 
planning for the next pregnancy. In our study,2 patients had previous 
history of GDM and among them one patient was found to have GDM in 
the current pregnancy also. 
Family history of diabetes: 
34 patients among the study participants had family history of 
diabetes mellitus. Among these 34 patients, eight patients had GDM in 
the current pregnancy. All these 8 patients had first degree relatives as a 
diabetic.  So, any woman with a diabetic first degree relative, should be 
aware of the risk she inherits and take preventive and precautionary 
measures right from the day she is planning to conceive to address the 
other modifiable risk factors. This would bring down the chances of her 
to get GDM. There was no significant difference between the WHO and 
ADA criteria in diagnosing GDM in this group. 
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Bad obstetric history:  
 Mothers with previous history of abortions should be screened for 
GDM and considered high risk to avoid any mishaps in the current 
pregnancy because,  literature have shown that patients with bad obstetric 
history have a higher chances of becoming GDM mothers compared to 
the general population.  In our study nine patients were found to have bad 
obstetric history. Among these patients 4 were found to have GDM in the 
current pregnancy which goes by the literature. There was no significant 
difference between the WHO and ADA criteria in diagnosing GDM in 
this group. 
Gestational age: 
 Mean age of diagnosis for GDM by both ADA and WHO criteria 
was found to be 26.1 weeks.  
Reliability of ADA criteria: 
 When compared with the gold standard WHO criteria, ADA 
criteria had sensitivity of 80.8% and specificity of 94.25%. 
 When plotted for ROC curve for different cut off points in the two 
criterias, blood sugar value at the end of two hours had the highest 
sensitivity and specificity whereas the fasting  blood sugar value had low 
sensitivity and specificity.  
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 From all these observations two points stand out from the others. 
1. Need for universal screening – must: 
From the data presented above, it is very clear that at least 
half the patients would have been missed from the diagnosis of 
GDM, if only the patients with high risk were to be screened. 
By universal screening as followed in this study the chances of 
picking up the GDM mothers would be doubled. This is more 
appropriate for the high risk ethnic group like us, Asians, 
suggested by literature. 
2. Resource poor setting: 
It would be cumbersome in resource poor settings to take 
two sugar levels as per WHO criteria and 3 sugar levels as per 
ADA criteria in resource poor settings like remote and 
underdeveloped areas. This study has shown that two hour 
sugar value has maximum sensitivity and specificity in 
diagnosing GDM and would pick up majority of the cases when 
performed between 24 and 28 weeks of gestation. Though this 
can’t replace the gold standard criteria, this can be seriously 
considered as the investigation of choice in resource poor 
settings. Similar results have been quoted in another study by 
Haritha Sagili et al[41] 
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3. Two hour glucose level: 
As per WHO criteria the cut off at the end of two hours for 
diagnosing GDM is 140mg/dl and that by ADA criteria is 
153mg/dl. When this single value is used for diagnosing GDM in 
our study, 28 patients would have been labeled as GDM as per 
WHO criteria against 23 patients as per ADA criteria. All these 28 
patients are labeled as GDM by either standard ADA or WHO 
criteria definitions. So, when a single value of two hour blood 
glucose level is to be decided, it would be desirable to have a cut 
off as 140mg/dl. 
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CONCLUSION: 
• There is no difference among the two recommendations both ADA 
and WHO in the diagnosis of GDM. 
• The 2 hour value done has the statistical significance in diagnosis 
of GDM. 
• The one hour value done in ADA criteria doesnot have statistical 
significance when compared to two hour value. 
• Risk factor analysis doenot have any statistical significance in 
diagnosis of GDM. 
• Hence universal screening for GDM is necessary to diagnose 
GDM.  
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PATIENT CONSENT FORM 
STUDY TITLE      :  A COMPARATIVE STUDY OF ADA & WHO CRITERIA 
FOR SCREENING  OF GESTATIONAL DIABETES 
MELLITUS  AND FOLLOW UP OF GDM  PATIENTS IN 
SALEM  
STUDY CENTRE     :  Department of Obstetrics and Gynaecology, GMKMCH Salem  
PARTICIPANT NAME :     AGE :   SEX:  
I.D. NO :  
I confirm that I have understood the purpose of study. I have the opportunity 
to ask the question and all my questions and doubts have been answered to my 
satisfaction.  
I have been explained about the possible complications that may occur during 
procedure. I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving any reason.  
I understand that investigator, regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study. I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law.   
I agree not to restrict the use of any data or results that arise from the study.  
I hereby consent to participate in this study.  
 
 
Time :  
Date :   
Place :   
Patient’name:  ______________________ 
signature / thumb impression of patient 
Signature of the investigator:   
Name of the investigator :  _____________ 
 
      
   
 
F M O F 1Hr 2 Hr
1
25 151 54 23.6831718 Y x x Nil Nil Nil
on 
thyroid
Nil 12.10.16 19.7.16 Primi 25 160 161 162 pos pos
2
22 149 52 23.4223684 x x x x Nil Nil Nil Nil Nil 5.10.15 12.7.16 G2 1 26 90 124 91 neg neg
3
25 157 55 22.3132784 x x x Nil Nil Nil Nil Nil 11.8.15 20.6.16 Primi - - 28 55 115 130 neg neg 
4
22 154 70 29.5159386 x x x Nil Nil Nil Nil Nil 7.11.15 14.8.10 Primi - - 26 87 118 90 neg neg
5
25 143 54 26.4071593 x x x present Nil Nil Nil Nil 10.11.15 17.8.16 2 1 0 24 84 105 92 NEG NEG
6
25 157 71 28.804414 x x x present Nil Nil Nil Nil 3.10.15 10.7.16 2 1 0 26 92 90 99 NEG NEG
7
22 162 53 20.1950922 x x x Nil Nil Nil Nil Nil Nil 17.11.15 24.8.16 Primi 26 70 101 112 NEG NEG
8
26 152 45 19.4771468 x x x - present - Nil Nil Nil 22.11.15 19.8.16 G2 1 0 24 75 193 187 neg POS
9
29 145 46 21.8787158 x x x - Nil
7 yrs 
1st 
child
Pre - - 13.12.15 20.9.16 G3 2
1st 
child 
died 
24 63 138 107 neg NEG
10
26 133 74 41.8339081 x y x + Nil Nil Nil Nil Nil 19.10.15 26.7.16 G2 1 Nil 28 102 168 127 NEG NEG
11
22 164 64 23.7953599 x x x
LBW child 
8th day
Nil Nil Nil Nil 14.10.15 21.7.16 G3 2 Nil 26 60 104 117 neg NEG
12
25 186 43 12.4291826 x x x Nil Nil Nil Nil Nil 12.10.15 19.7.16 Primi 24 60 104 117 neg NEG
13
25 158 69 27.6398013 x x sirtim - - Nil Nil Nil 5.10.15 12.7.16 G2 1 Nil 25 56 149 132 neg NEG
14
21 181 59 18.0092183 x x x - - Nil Nil Nil 12.12.15 19.9.16 G2 1 Nil 26 60 102 118 neg NEG
A STUDY ON GDM
Sl. 
No
Age Ht 
(cm)
Wt
(Kg)
BMI Family H/o Obese BOH Deliver
y 
Hyper 
tension
Thyroid 
disorde
Previou
s 
LMP EDD 75 gm OGTT WHO ADAGravid
a
PARA Abotrio
ns
GA
15
35 152 79 34.1932133 x x x - Nil
Yes 3.7 
kg 2nd 
child
Nil Nil Nil 24.12.15 31.9.16 G3 2 Nil 26 49 68 98 neg NEG
16
19 154 52 21.9261258 Nil Nil NIl Nil Nil Nil Nil Nil Nil 1.11.15 8.8.15 primi 0 0 24 51 155 127 neg NEG
17
19 165 80 29.3847567 + - - - - - + Nil Nil 30.11.15 6.9.16 Primi 24 68 131 80 neg NEG
18
27 162 60 22.8623685 Nil Nil NIl Nil - - Nil Nil Nil 11.9.15 12.6.16 Primi 28 81 120 131 NEG NEG
19
21 168 75 26.5731293 Nil Nil NIl Nil +
1st 
child 4 
kg
Nil Nil Nil 19.11.15 26.8.16 G3 1 1 28 52 138 101 NEG NEG
20
24 152 49 21.2084488 Nil Nil NIl Nil - Nil Nil Nil 25.11.15 2.9.16 Primi 28 60 120 102 NEG NEG
21
24 152 47 20.3427978 Nil Nil NIl Nil Nil - - - - 8.12.15 15.9.16 2 1 1 26 76 137 150 POS NEG
22
20 156 44 18.0802104 Nil Nil NIl Nil Nil Nil Nil Nil Nil 18.10.15 25.7.16 Primi - - 28 71 112 90 neg neg
23
24 150 57 25.3333333 Nil Nil NIl Nil Nil Nil Nil Nil Nil 11.10.18 18.7.16 Primi 28 65 110 98 neg neg
24
23 147 43 19.8991161 Nil Nil NIl Nil Nil Nil Nil Nil Nil 7.10.16 14.7.16 3 2 1 27 54 96 105 neg neg
25
31 151 64 28.0689443 - Nil NIl Nil x Nil Nil Nil Nil 11.12.16 18.9.16 G3 1 1 24 104 123 119 neg neg
26
20 153 53 22.6408646 nil nil nil - - - - - 20.10.15 27.7.16 Primi 28 70 92 142 pos neg
27
25 160 52 20.3125 Nil x NIl - - 2 - - - 19.10.16 26.7.16 G4 3 1 28 72 132 109 neg neg
28
20 157 48 19.4734066 - - - - - Primi - - - 18.11.15 25.8.16 Primi 26 88 110 99 neg neg
29
20 148 44 20.0876552 - - - - - Nil - - - 10.10.15 17.7.16 G2 1 - 26 83 89 68 neg neg
30
22 148 44 20.0876552 - - - - - 3.25 - - - 10.12.15 17.9.16 G2 1 - 24 70 140 98 neg neg
31
28 147 46 21.2874265 - - - - 2 - - - - 24.11.15 31.9.16 G4 1 2 24 57 132 72 neg neg
32
21 158 63 25.2363403 - - - - 2 3.8 - - - 8.12.15 15.9.16 G4 1 2 24 55 110 63 neg neg
33
19 154 52 21.9261258 - - - - - - - - - 1.11.15 8.8.16 Primi 26 63 138 107 neg neg
34
23 150 49 21.7777778 - - - - - - - - 21.10.15 28.7.16 G2 P1 - 26 84 136 121 neg neg
35
25 151 57 24.9989036 Y - - - present
1st 
child 
3 5 kg
- - - 4.11.15 11.8.16 G4 P1 A2 24 88 132 117 NEG NEG
36
21 143 37 18.0937943 Nil Nil NIl Nil Nil Nil - - - 22.12.15 28.9.16 Primi - - 24 92 170 122 NEG neg
37
28 155 56 23.3090531 - - - - - - - - 5.11.15 12.8.16 G3 1 1 26 87 100 120 neg NEG
38
35 145 52 24.7324614 nil - - - present
4th 
child 
3 75kg
- - - 1.12.15 8.9.16 G5 1 3 24 54 81 90 neg NEG
39
23 159 58 22.9421305 - - - - - 3.3kg - - - 16.11.15 23.8.16 G2 1 - 24 78 141 135 neg NEG
40
28 165 60 22.0385675 - - - - -
3.7kg 
1st chid
- - - 21.12.15 28.9.16 G3 1 1 24 70 135 112 neg NEG
41
40 152 63 27.2680055 - - - +
present[i
ud]
Nil - - - 3.1.16 30.10.16 G3 2 - 24 81 195 210 POS POS
42
28 159 50 19.7776987 - - - - - - - - - 4.12.15 11.9.16 G4 3 - 24 84 159 139 neg NEG
43
21 156 55 22.600263 - - - - nil
1st 
child 
3 5 kg
- - - 26.11.15 3.9.16 G3 1 1 28 70 97 74 neg NEG
44
23 160 52 20.3125 - - - - - - - - - 11.11.15 18.8.16 Primi 26 97 103 85 neg NEG
45
30 148 51 23.2834186 - - - - - 3.75kg - - - 1.12.15 8.9.16 G2 1 - 26 98 199 159 POS pos
46
32 155 76 31.6337149 ~~ ~ ~ ~ `~ ~ - - - 21.11.15 28.8.16 G2 1 - 24 62 101 128 neg NEG
47
25 140 35 17.8571429 - - - - ~ - - - - 15.12.15 22.9.16 G2 0 1 25 60 127 98 neg NEG
48
27 147 65 30.0800592 - - - - Nil - - Present - 1.11.15 8.8.16 G2 1 - 26 70 135 112 neg NEG
49
26 153 40 17.087445 - - - - - - - - - 15.1.16 22.10.16 G2 1 26 73 132 103 neg NEG
50
31 143 68 33.2534598 - - - + 1 - - - - 14.12.16 21.9.16 3 1 1 24 65 120 77 neg NEG
51
21 152 59 25.5367036 - - - - 1 - - - 22.11.15 29.8.16 3 1 1 24 65 104 81 neg Neg
52
28 152 53 22.9397507 - - - - - - - - 17.11.15 24.8.16 3 2 - 80 110 103 NEG NEG
53
31 158 40 16.0230732 - - - - - - - - 28.12.15 5.10.16 2 1 - 26 78 109 94 NEG NEG
54
32 156 75 30.8185404 ~ ~ ~ ~ ~ 4 KG ~ ~ ~ 13.12.15 20.09.16 5 1 3 26 73 172 149 pos NEG
55
23 153 41 17.5146311 ~ ~ ~ ~ ~ ~ ~ `~ ~ 30.12.15 07.06.16 primi 28 78 116 93 neg NEG
56
25 155 55 22.89282 ~ present ~ `~ ~ ~ ~ ~ ` 24.12.15 1.10.16 primi 2 76 157 108 neg NEG
57
38 150 48 21.3333333 ~ present ~ ~ ~ ~ ~ ~ ~ 1.1.16 8.10.16 primi 28 91 174 169 pos pos
58
25 160 67 26.171875 present present ~ ~ 1 3.6 s ~ ~ 4.1.16 11.10.16 3 1 1 24 78 122 108 neg NEG
59
20 163 50 18.8189243 ~ ~ ~ ~ ~ `~ ~ `~ ~ 19.12.15 26.9.16 primi 24 78 99 73 neg NEG
60
26 144 37 17.8433642 ~ ~ ~ ~ ~ 3.2 ~ ~ ~ 26.12.15 3.10.16 3 2 26 60 108 116 neg NEG
61
28 148 69 31.5010957 + 12.10.15 19.7.16 2 1 28 74 137 121 neg NEG
62
72 148 49 22.3703433 ~ present ~ ~ ~ ~ ~ `~ ~ 5.2.16 12.11.16 primi 24 72 143 130 neg NEG
63
29 155 69 28.7200832 `~ present ~ ~ ~ `~ ~ `~ ~ 8.1.16 15.10.16 primi 24 64 138 108 neg NEG
64
20 159 44 17.4043748 present present present 1 6.1.16 13.10.16 2 1 24 60 105 71 neg Neg
65
26 136 39 21.0856401 `~ ~ ~ 2.6 ~ ~ ~ 15.11.16 27.10.16 2 1 24 79 125 101 neg Neg
66
23 162 70 26.6727633 ~ ~ ~ + 3.15 ~ ~ ~` 26.12.16 4.10.16 3 1 1 26 89 110 123 neg Neg
67
21 154 73 30.7809074 ~ present ~ ~ ~ ~ ~ ~ `~ 20.11.15 27.8.16 primi 28 60 92 79 neg Neg
68
21 142 52 25.788534 ~ + ~ ~ `~ ~ ~ ~ ~ not known
scan wise 
8.11.16
2 1 28 79 120 134 neg Neg
69
20 149 56 25.224089 ~ ~ ~ ~ ~ `~ ~ ~ `~ 2.1.16 9.10.16 primi 28 69 97 87 neg Neg
70
23 156 46 18.9020381 `~ ~ ~ ~ 2.6 ~ ~ ~ not known
2.10.16sca
n wise
2 1 26 80 128 99 neg Neg
71
21 150 60 26.6666667 ~ + ~ ~ ~ 2.8 ~ ~ ~ 12.2.16 19.11.16 2 1 24 66 118 86 neg Neg
72
23 151 60 26.3146353 ~ ~ ~ ~ ~ 2.7 ~ ~ ~ 19.12.15 26.9.16 2 1 24 94 164 86 neg Neg
73
23 148 56 25.5661066 ~ ~ ~ ~ ~ 3 ~ ~ ~ 20.1.16 27.10.16 2 1 26 74 82 96 neg Neg
74
22 135 48 26.3374486 present ~ ~ ~ ~ ~ ~ ~ ~ 19.12.15 26.9.16 primi 28 62 77 70 neg Neg
75
27 133 44 24.8742156 ~ ~ ~ ~ ~ 3 ~ ~ ~ 21.1.16 28.10.16 2 1 24 90 121 159 pos pos
76
24 150 58 25.7777778 present ~ ~ + ~ ~ ~ ~ ~ 30.12.15 .7.10.16 primi 28 95 120 110 neg Neg
77
23 154 56 23.6127509 present ~ ~ ~~ ~ 3.6 ~ ~ ~ 24.1.16 1.11.16 3 1 1 26 75 139 155 pos pos
78
29 150 60 26.6666667 ~ ~ ~ ~ ~ ~ ~ ~ ~ 2.12.15 9.9.16 3 1 1 24 68 113 102 neg Neg
79
22 154 50 21.0828133 ~ ~ ~ ~ ~ ~ ~ ~ ~ 10.12.15 17.9.16 primi 24 79 125 101 NEG NEG
80 23 165 86 31.5886134 + ~ ~ + ~ ~ ~ ~ ~ 9.2.16 16.11.16 primi 26 87 160 128 NEG NEG
81 25 156 55 22.600263 ~ ~ ~ ~ ~ ~ ~ ~ ~ 11.11.15 18.8.16 primi 24 61 104 64 NEG NEG
82 22 152 49 21.2084488 present ~ ~ ~ ~ 4.05 ~ ~ ~ 20.12.15 22.8.16 2 1 25 78 119 101 NEG NEG
83 20 149 59 26.5753795 ~ ~ ~ ~ ~ ~ ~ ~ ~ 23.11.15 30.8.16 primi 25 77 109 81 NEG NEG
84 20 155 58 24.1415193 ~ ~ ~ ~ ~ ~ ~ ~ ~ 7.2.16 14.11.16 primi 24 82 143 99 NEG NEG
85 26 157 58 23.5303663 ~ present ~ ~ ~ ~ ~ ~ ~~ 23.1.16 30.10.16 primi 26 69 98 112 NEG NEG
86 26 155 62 25.8064516 ~ ~ ~ ~ ~ 2.45 ~ ~ ~ 17.1.16 24.10.16 2 1 28 60 108 116 NEG NEG
87 19 150 70 31.1111111 ~ ~ GM ~ ~ ~ ~ ~ ~ 18.11.15 25.8.16 primi 26 78 82 109 NEG NEG
88 21 149 48 21.6206477 ~ ~ ~ ~ ~ 3.5 ~ ~ ~ 23.12.15 30.9.16 2 1 24 70 107 96 NEG NEG
89 24 149 59 26.5753795 present present ~ ~ ~ 3.7 ~ ~ ~ 18.1.16 25.10.16 2 1 25 59 198 133 NEG POS
90 27 155 56 23.3090531 ~ ~ ~ ~ ~ 3.75 ~ ~ ~ 26.1.16 3.11.16 2 1 24 67 101 118 NEG NEG
91 36 152 60 25.9695291 present ~ ~ ~ ~ 3.75 ~ ~ ~ 21.1.16 28.2 2 1 25 75 120 165 POS POS
92 20 165 48 17.630854 ~ ~ ~ ~ ~ ~ ~ ~ ~ primi 24 78 112 108 NEG NEG
93 20 160 55 21.484375 ~ ~ ~ ~ ~ ~ ~ ~ ~ 21.1.16 27.10.16 primi 24 81 112 96 NEG NEG
94 27 143 48 23.4730305 ~ ~ ~ ~ ~ 3 ~ ~ ~ 22.11.15 28.8.16 3 2 26 80 115 122 NEG NEG
95 26 152 53 22.9397507 ~ ~ ~ ~ ~ 2.8 ~ ~ ~ 18.2.16 25.11.16 3 2 25 74 124 70 NEG NEG
96 23 150 58 25.7777778 ~ ~ ~ ~ ~ ~ ~ ~ ~ 21.2.16 27.10.16 28 72 88 82 NEG NEG
97 23 151 60 26.3146353 ~ ~ ~ ~ ~ ~ ~ ~ ~` 20.2.16 27.10.16 Primi 28 70 125 73 neg NEG
98 20 150 62 27.5555556 ~ ~ ~ ~ ~ ~ ~ ~ `~ 25.2.16 2.12.16 primi 26 61 86 64 NEG NEG
99 26 164 78 29.0005949 ~ ~ ~ ~ ~ ~ ~ ~ ~ 31.12.15 1.10.16 2 1 28 76 83 72 neg neg
100 25 154 68 28.6726261 ~ ~ ~ `~ ~ ~ ~ ~ ~ 16.2.16 23.11.16 primi 24 76 141 96 neg neg
101 23 165 86 31.5886134 Y - - + - - - If not on th - NK NK primi 28 87 160 128 NEG NEG
102 25 156 55 22.600263 - - - - - - - - - 11.11.15 18.8.16 Primi 28 61 104 64 NEG NEG
103 25 152 40 17.3130194 - - - - - - - - - 8.1.16 15.10.16 2 1 - 26 80 120 90 neg NEG
104 22 152 49 21.2084488 - - - - - 4.05k - - - 20.12.15 27.9.16 2 1 - 24 78 119 101 NEG NEG
105 20 149 59 26.5753795 - - - - - - - - - 23.11.15 30.8.16 Primi - 28 90 129 113 NEG NEG
106 20 155 58 24.1415193 - - - - - - - - - 7.2.16 14.11.16 Primi 24 82 143 99 NEG NEG
107 26 157 58 23.5303663 - - - - - - - - - 23.1.16 30.10.16 Primi 28 69 98 112 NEG NEG
108 26 155 62 25.8064516 - - - - - - - - 17.1.16 24.10.16 2 1 28 87 113 102 NEG NEG
109 19 150 70 31.1111111 - - Grand mother - - - - - - 18.11.15 25.8.16 Primi 26 95 170 156 POS POS
110 30 149 50 22.521508 - - - - - 3.5kg - - - 24.11.15 31.8.16 3 2 28 88 122 109 NEG NEG
111 22 160 46 17.96875 - - - - - - - - - 14.1.16 21.10.16 Primi 28 89 180 160 POS POS
112 28 156 66 27.1203156 - - - - - - - - - 18.1.16 25.10.16 2 1 24 87 160 160 pos POS
113 21 149 48 21.6206477 - - - - - 3.5 kg - - - 23.12.15 30.9.16 2 1 28 70 107 96 NEG NEG
114 24 149 59 26.5753795 - - - - - 3.7 kg - - - 18.1.16 25.10.16 2 1 28 78 196 188 POS POS
115 28 154 63 26.5643447 - - - - - 4 kg - - - 14.2.16 21.11.16 2 1 28 68 101 90 NEG NEG
116 20 151 50 kg #VALUE! - - - - - - - - - 11.1.16 18.10.16 primi 28 81 195 210 pos POS
117 23 158 44 17.6253805 - - - - - - - - - 1.12.2016 7.9.2016 2 1 - 24 88 120 101 NEG NEG
118 27 195 56 14.7271532 - - - - - 3.75 kg - - - 26.1.16 3.11.16 2 1 - 26 85 108 97 NEG NEG
119 28 155 52 21.6441207 - - - - - - - - - 24.1.16 31.10.16 Primi - - 26 89 143 130 NEG NEG
120 36 152 60 25.9695291 Y - - - - - - - + 21.1.16 28.10.16 2 1 - 28 75 120 165 POS POS
121 20 165 48 17.630854 - - - - - - - - - Primi 24 78 90 108 NEG NEG
122 20 160 55 21.484375 - - - - - - - - - 4.2.16 11.11.16 Primi - - 24 80 89 106 NEG NEG
123 20 165 69 25.3443526 - - - - - - - - - 20.1.16 27.10.16 Primi 26 81 88 96 NEG NEG
124 27 143 48 23.4730305 - - - - - - - - - 21.11.15 28.8.16 3 2 - 26 80 77 122 NEG NEG
125 21 45 #DIV/0! - - - - - - - - - 16.12.15 23.9.16 2 1 - 26 90 88 97 NEG NEG
126 27 152 63 27.2680055 - - - - Y - - 7.12.15 14.9.16 2 1 - 28 103 82 109 NEG NEG
127 20 148 43 19.6311176 - - - - - - - - - 20.1.16 27.10.16 Primi Nil 28 116 125 172 NEG POS
128 27 153 46 19.6505617 - - - - - - - - - 13.1.16 20.10.16 Primi - 28 114 123 166 NEG POS
129 26 152 53 22.9397507 - - - - - - - - - 18.2.16 25.11.16 3 2 28 74 124 70 NEG NEG
130 20 158 47 18.827111 - - - - - - - - - 18.2.16 25.11.16 Primi 24 47 192 180 POS POS
131 20 152 45 19.4771468 - - - Primi 10.12.15 17.9.16 - 36 61 99 94 NEG NEG
132 29 147 40 18.5108057 - + - - - - 16.2.16 28.11.16 93 Po A2 24 70 98 97 NEG NEG
133 23 150 58 25.7777778 - - - - - - 21.02.16 27.10.16 - 26 72 88 82 NEG NEG
134 26 164 78 29.0005949 Y - - - - - - - 31.12.15 7.10.16 Primi - - 28 101 123 112 NEG NEG
135 25 152 53 22.9397507 - - - - - - - - 4.2.16 11.11.16 2 - - 28 89 111 101 NEG NEG
136 19 158 53 21.230572 - - - - - - - - - 23.1.16 30.10.16 Primi - - 26 63 82 78 NEG NEG
137 19 153 47 20.0777479 - - - - - - - - - 24.2.16 1.12.16 Primi - - 24 89 120 93 NEG NEG
138 19 159 50 19.7776987 - - - - - - - - - 2.2.16 7.11.16 Primi - - 28 73 133 104 NEG NEG
139 30 147 75 34.7077607 14.2.16 21.11.16 primi 28 77 100 97 neg neg
140 26 159 57 22.5465765 12.3.16 19.12.16 primi 26 86 111 101 NEG NEG
141 27 15 62 2755.55556 19.2.16 26.11.16 primi 28 82 102 97 NEG NEG
142 22 151 43 18.858822 4.4.16 11.11.17 primi 28 83 101 98 NEG NEG
143 25 140 46 23.4693878 not known not known primi 24 91 119 102 NEG NEG
144 39 144 45 21.7013889 27.1.16 5.10.16 PRIMI 28 82 170 156 POS POS
145 26 144 46 22.183642 30.1.16 1210.16 PRIMI 28 86 134 111 NEG NEG
146 24 154 56 23.6127509 19.12.15 26.9.15 PRIMI 26 83 123 104 NEG NEG
147 #DIV/0! - - - - - - - - - 05.12.15 12.9.16 primi 28 75 163 155 NEG POS
148 32 144 68 32.7932099 Y - - - + - - - - 15.12.15 22.9.16 3 1 1 28 77 120 146 pos NEG
149 31 141 54 27.1616116 26.1.16 2.11.16 PRIMI 28 79 273 207 pos POS
150 20 143 43 21.0279231 NK NK PRIMI 26 67 116 101 NEG NEG
151 22 150 54 24 2.11.15 8.8.16 PRIMI 28 87 121 114 NEG NEG
152 21 156 70 28.7639711 2.2.16 9.11.16 PRIMI 24 77 156 145 pos NEG
153 39 150 58 25.7777778 17.3.16 24.12.16 PRIMI 24 89 121 117 NEG NEG
154 22 149 51 22.9719382 Y 25.12.15 1.10.16 PRIMI 24 88 130 99 NEG NEG
155 22 163 61 22.9590877 Y 25.11.15 2.9.16 3 2 26 90 120 112 NEG NEG
156 28 151 45 19.7359765 1.3.16 8.12.16 2 1 26 85 152 86 NEG NEG
157 21 162 53 20.1950922 - Y - - - - - - - 10.2.16 17.11.16 Primi - - 28 82 92 80 NEG NEG
158 23 144 40 19.2901235 - - - - - - - - Not known 25.11.16 G2 1 - 28 87 175 166 POS POS
159 27 151 61 26.7532126 - - - - - - - - Not known 6.9.16 3 1 1 24 88 111 96 NEG NEG
160 20 150 50 22.2222222 Y Y - - - - - - - 20.12.15 27.9.16 Primi 28 86 113 93 NEG NEG
161 30 148 56 25.5661066 - - - - 1 - - - - 23.12.15 30.9.16 4 2 1 28 89 144 136 NEG NEG
162 21 156 70 28.7639711 - - - - - - - - - 2.2.16 9.11.16 Primi 26 65 132 78 NEG NEG
163 24 163 56 21.0771952 - - - Nil Nil - - - 22.11.15 29.8.16 Primi 26 20 102 98 NEG NEG
164 28 159 58 22.9421305 - - - + - - - - 16.2.16 23.11.16 G4 P2 1 28 94 166 153 neg POS
165 20 154 66 27.8293135 - - - - - - - 1.1.16 8.10.16 Primi 0 24 85 109 96 NEG NEG
166 27 150 42 18.6666667 - - - + - - - - 17.1.16 24.10.16 G5 - 4 24 87 118 102 NEG NEG
167 22 #DIV/0! - - - - - 3.8 kg - - - 14.01.16 21.10.16 2 - - 28 67 130 105 NEG NEG
168 28 145 65 30.9155767 - - - 3.5 kg - - - 2.2.16 9.1.16 2 - - 26 75 132 112 NEG NEG
169 28 150 38 16.8888889 - - - - 3.3 kg - - - 5.2.16 12.11.16 2 - - 24 89 160 156 NEG POS
170 27 65 #DIV/0! - - - - - - 6.2.16 13.11.16 Primi 26 89 141 119 NEG NEG
171 22 157 65 26.3702381 - - - - - 3.5 kg - - - 4.1.16 11.10.16 3 1 1 28 89 196 190 POS POS
172 25 138 39 20.478891 - - - - - - - - 3.2.16 10.11.16 2 1 - 28 73 102 111 NEG NEG
173 27 142 50 24.7966673 - - - - - - 19.2.16 26.11.16 Primi - - 28 90 87 97 NEG NEG
174 27 156 62 25.4766601 - - - 21.2.16 28.11.16 PRIMI 28 83 101 91 NEG NEG
175 23 154 91 38.3707202 Y - - 22.3.16 29.12.16 PRIMI 28 90 89 87 NEG NEG
176 27 151 51 22.36744 - - - Y - - - 4.1.16 11.10.16 2 1 2 26 86 112 88 NEG NEG
177 30 148 55 25.109569 - - - - - - - - - 17.2.16 23.11.16 2 1 - 28 77 89 86 NEG NEG
178 20 151 41 17.9816675 - - - - - - - - - 301.16 7.11.16 Primi - - 28 78 98 88 NEG NEG
179 29 152 40 17.3130194 - - - - - - - - - 26.12.15 2.10.16 3 2 - 28 81 111 81 NEG NEG
180 19 155 46 19.1467222 - - - - - - - - - 29.2.16 7.12.16 Primi - - 24 60 108 129 neg NEG
181 27 53 - - - 13.3.16 20.12.16 PRIMI 26 84 142 131 NEG NEG
182 23 164 51 18.9619274 - - - 11.04.16 18.1.17 PRIMI 28 89 120 92 NEG NEG
183 23 154 56 23.6127509 - - - 2.5 kg 4.1.16 11.10.16 3 1 A1 24 77 164 156 POS POS
184 28 146 45 21.1109026 - - - - - - - - 20.5.16 27.2.17 2 1 1 28 78 92 119 neg NEG
185 38 151 59 25.8760581 Y - - - - - - - - 24.2.16 30.11.16 3 2 - 28 81 135 120 neg NEG
186 32 145 50 23.7812128 - - - - - - - - - 2.2.16 9.11.16 4 2 1 28 76 150 138 neg NEG
187 24 154 50 21.0828133 - - - - - - - - - 8.3.16 15.12.16 2 1 - 26 71 175 167 pos POS
188 31 151 54 23.6831718 - - - - - - - - - 17.12.16 24.11.16 3 1 1 28 92 139 82 NEG NEG
189 21 154 57 24.0344072 - - - - - - 8.3.16 15.12.16 primi - - 28 52 91 70 NEG NEG
190 21 161 50 19.2893793 - - - - - 2.5 kg - - - 20.3.15 27.12.16 2 1 - 26 92 90 99 NEG NEG
191 24 151 68 29.8232534 - - - - - 2.75 kg - - 6.2.16 13.11.16 2 1 - 24 74 95 82 NEG NEG
192 21 148 49 22.3703433 - - - - - 2.3 kg - - - 29.1.16 5.11.16 2 1 - 28 84 105 92 NEG NEG
193
29 143 43 21.0279231 - - - - - 2.5 Kg2.25 KG - - - 19.2.16 26.11.16 3 2 - 28 77 108 80 NEG NEG
194 26 154 83 34.9974701 - - - + - - + - 12.1.16 19.10.16 primi 24 80 110 82 NEG NEG
195 31 155 75 31.2174818 - - - + - - - - 17.1.16 24.10.16 4 3 2 28 88 119 91 NEG NEG
196 22 153 40 17.087445 - - - - - - - - 15.1.16 22.10.16 Primi 26 99 130 108 NEG NEG
197 22 148 34 15.522279 - Y - - - - - - - 11.12.2015 18.9.2016 3 1 1 28 98 199 159 POS POS
198 24 157 51 20.69049454 - - - - - - - - - 17.1.2016 24.10.2016 primi 27 96 99 108 NEG NEG
199 23 154 54 22.76943835 - - - - - - - - - 22.1.2016 29.10.2016 primi 25 95 105 114 NEG NEG
200 21 168 62 21.96712018 - - - - - - - - 05.2.2016 12.11.2016 2 1 26 80 112 120 NEG NEG
